Condensed Statements of Cash Flows - USD ($)		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Cash Flows From Operating Activities
Net loss		$ (5,739,366)	$ (7,339,665)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		819,064	908,987
Depreciation of property and equipment		63,119	75,432
Amortization of debt discount		149,490	26,215
Amortization of operating lease right-of-use asset		133,907	89,718
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(212,025)	(907,774)
License fee and expense reimbursements receivables		210,109	440,756
Deferred clinical supply costs		(1,067,714)
Accounts payable		(26,207)	(79,340)
Accrued compensation		(1,110,002)	(868,224)
Accrued expenses and other current liabilities		(42,933)	(441,012)
Lease liabilities		(136,150)	(89,492)
Net Cash Used In Operating Activities		(6,958,708)	(8,184,399)
Cash Flows From Investing Activities
Purchases of property and equipment		(920,865)	(174,567)
Vendor deposits for property and equipment		82,813	(33,095)
Net Cash Used In Investing Activities		(838,052)	(207,662)
Cash Flows From Financing Activities
Proceeds from sale of common stock and warrants in direct offering	[1]		14,981,299
Proceeds from sale of common stock in At the Market offering	[2]	3,607,827	860,365
Payment of issuance costs for At the Market offering		(108,235)
Repayments of notes payable		(100,030)	(111,793)
Payment of offering issuance costs			(83,391)
Net Cash Provided By Financing Activities		3,399,562	15,646,480
Net (Decrease) Increase in Cash and Cash Equivalents		(4,397,198)	7,254,419
Cash, cash equivalents and restricted cash - Beginning of Period		22,863,520	27,336,850
Cash, cash equivalents and restricted cash - End of Period		18,466,322	34,591,269
Cash, cash equivalents and restricted cash consisted of the following:
Cash and cash equivalents		18,466,322	26,716,269
Restricted cash			7,875,000
Total		18,466,322	34,591,269
Supplemental Disclosure of Cash Flow Information:
Interest		304,512	95,585
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Purchase of insurance premium financed by note payable		609,140	675,331
Recognition of right-of-use asset for lease liability upon adoption of ASU 2016-02			618,906
Right-of-use assets obtained in exchange for lease liabilities		350,473	79,181
Cashless exercise of stock options		$ 2
Issuance of common stock related to vested restricted stock units			$ 2

[1] Includes gross proceeds of $14,981,299, of which $5,741,299 is pre-funded warrants.

[2] Includes gross proceeds of $886,974, less total issuance costs of $26,609